AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results

  AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results

Business Wire

WEST CHESTER, Ohio -- February 4, 2014

AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device
provider, will release its financial results for the fourth quarter and full
year 2013 on Thursday, February 27, 2014.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday,
February 27, 2014 to discuss its fourth quarter and full year 2013 financial
results. A live webcast of the conference call will be available online from
the investor relations page of AtriCure’s corporate website at
www.atricure.com.

Pre-registration is available and recommended for this call at the following
URL:

https://www.theconferencingservice.com/prereg/key.process?key=P9XLYTNAL

You may also access this call through an operator by calling (888) 713-4214
for domestic callers and (617) 213-4866 for international callers at least 15
minutes prior to the call start time using reservation code 59283031.

The webcast will be available on AtriCure’s website and a telephonic replay of
the call will also be available through March 27, 2014. The replay dial-in
numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for
international callers. The reservation code is 68935249.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide.The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
or
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.